1 / 15

Entrepreneurship in Biotechnology

Entrepreneurship in Biotechnology. Columbia University Graduate School of Arts and Sciences BIOT 4180. Week 11. Partnering, Mergers and Acquisitions and Exits. Small Company Perspective. Late clinical and regulatory experience Risk mitigation Orphan drug sales force: 15+

main
Télécharger la présentation

Entrepreneurship in Biotechnology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180

  2. Week 11 Partnering, Mergers and Acquisitions and Exits Columbia University GSAS BIOT 4180

  3. Small Company Perspective • Late clinical and regulatory experience • Risk mitigation • Orphan drug sales force: 15+ • Blockbuster drug sales force: 3000+ • Cost of sales person: $300,000- 400,000 • Minimal overlap in skill sets between development, regulatory and sales Columbia University GSAS BIOT 4180

  4. Large Company Perspective • Cash flow • Product(s) • Pipeline • Platform • Leverage existing assets (sales force eg) Columbia University GSAS BIOT 4180

  5. Good and Bad Deals • Roche acquiring Genentech • Herceptin, Avastin, Lucentis • Pfizer acquires Warner Lambert • Lipitor • Pfizer acquires Esperion • Nothing for 1.3B Columbia University GSAS BIOT 4180

  6. 2003: MedivationinlicensesDimebon • Sep 2006: Dimebon meets 5/5 endpoints at 6 months Columbia University GSAS BIOT 4180

  7. June 2007: Dimebon benefits last 12 months Columbia University GSAS BIOT 4180

  8. July 2008: Dimebon data published in Lancet • Sep 2008: Pfizer deal announced Columbia University GSAS BIOT 4180

  9. Deal variables • Upfront payment • Milestone payments • Royalties • Costs and profits • Manufacturing • Geography • Co-promotion • Options • Contingent variable rights / other indications Columbia University GSAS BIOT 4180

  10. Dimebon licensing deal • 225M upfront payment • 500M on approval • 60:40 costs and profit split Columbia University GSAS BIOT 4180

  11. Mar 2010 Dimebon fails pivotal trial Columbia University GSAS BIOT 4180

  12. Stock vs Cash • Stock as currency: implicit admission that the stock is over-valued • Cash: straight-forward DCF calculation w/o need to include a “stock price currency exchange”

  13. Columbia University GSAS BIOT 4180

  14. Columbia University GSAS BIOT 4180

  15. Negotiation • Dealing from strength • Multiple buyer dynamic • Never have no options • Walking away • Most programs / companies are bought, not sold

More Related